COVID-19 Resource Center

COVID-19 Resource Center

Disclosures: Barouch reports receiving grants from Alkermes, amfAR, the Bill and Melinda Gates Foundation, Cure Vac, the Defense Advanced Research Projects Agency, Gilead Sciences, the Henry M. Jackson Foundation of the Walter Reed Army Institute of Research, Intima, Legend, Mass CPR, NIH, Ragon Institute, Sanofi, South Africa Medical Research Council, and Zentalis; receiving personal fees from SQZ Biotech; and having a patent for COVID-19 vaccines licensed to Janssen with no premarket royalties or payments of any kind. Please see the study for all other authors’ relevant financial disclosures.
June 08, 2021
1 min read
Save

COVID-19 vaccines highly immunogenic in pregnant and lactating women, study shows

Disclosures: Barouch reports receiving grants from Alkermes, amfAR, the Bill and Melinda Gates Foundation, Cure Vac, the Defense Advanced Research Projects Agency, Gilead Sciences, the Henry M. Jackson Foundation of the Walter Reed Army Institute of Research, Intima, Legend, Mass CPR, NIH, Ragon Institute, Sanofi, South Africa Medical Research Council, and Zentalis; receiving personal fees from SQZ Biotech; and having a patent for COVID-19 vaccines licensed to Janssen with no premarket royalties or payments of any kind. Please see the study for all other authors’ relevant financial disclosures.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Both messenger RNA COVID-19 vaccines available in the United States trigger immune responses in pregnant and nonpregnant women, including those who are lactating, researchers reported in JAMA.

Dan H. Barouch, MD, PhD, director of the Center for Virology and Vaccine Research at Beth Israel Deaconess Medical Center in New York, and colleagues conducted an exploratory, descriptive, prospective cohort study among 103 women aged 18 to 45 years who received an mRNA COVID-19 vaccine from December through March, or who had COVID-19 from April 2020 to March 2021.

 Source: Adobe Stock
Source: Adobe Stock.

Among the 103 participants, 30 were pregnant, 16 were lactating. Samples were obtained a medium of 21 days (interquartile range [IQR], 17-27 days) after the second dose from nonpregnant women, 21 days (IQR, 14-36 days) from pregnant women and 26 days (IQR, 19-31 days) from lactating women. Nine pregnant women gave birth during the trial and offered their infant’s cord blood.

Among all trial participants, 56 (54%) had received the Pfizer-BioNTech vaccine and the rest received the Moderna vaccine. Five pregnant participants (17%) received their first dose during their first trimester, 15 (50%) in their second and 10 (33%) in their final trimester.

The authors reported humoral and cellular immune response against wild-type SARS-CoV-2 strain and the Alpha and Beta variants.

According to the findings, two doses of the vaccines produced similar levels of antibody function and T-cell responses in all participants after their second vaccine dose, and all participants developed cross-reactive immune responses against the Alpha and Beta variants. Moreover, the researchers found that mothers transferred antibodies to infant cord blood and breast milk.

“Our data show that the mRNA vaccines are highly immunogenic in pregnant and lactating women, and that vaccinated women may transfer antibodies to their infants by cord blood and breastfeeding,” Barouch told Healio. “These findings, together with other data in the field, support the use of COVID-19 vaccines in pregnant and lactating women.”